JP2008050367A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008050367A5 JP2008050367A5 JP2007287366A JP2007287366A JP2008050367A5 JP 2008050367 A5 JP2008050367 A5 JP 2008050367A5 JP 2007287366 A JP2007287366 A JP 2007287366A JP 2007287366 A JP2007287366 A JP 2007287366A JP 2008050367 A5 JP2008050367 A5 JP 2008050367A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- patient
- cardiovascular
- composition
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000271 cardiovascular Effects 0.000 claims 9
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N Ethyl eicosapentaenoic acid Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 claims 3
- 101710010865 HMGCR Proteins 0.000 claims 3
- 102100010498 HMGCR Human genes 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 101700057694 mvaA Proteins 0.000 claims 3
- 229960002965 Pravastatin Drugs 0.000 claims 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N Pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 2
- 210000002966 Serum Anatomy 0.000 claims 2
- RYMZZMVNJRMUDD-HGQWONQESA-N Simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 229960005370 atorvastatin Drugs 0.000 claims 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 2
- 125000004494 ethyl ester group Chemical group 0.000 claims 2
- 229960002600 icosapent ethyl Drugs 0.000 claims 2
- 229960002855 simvastatin Drugs 0.000 claims 2
- 210000004351 Coronary Vessels Anatomy 0.000 claims 1
- 206010062060 Hyperlipidaemia Diseases 0.000 claims 1
- 208000010125 Myocardial Infarction Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 238000007887 coronary angioplasty Methods 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000002537 thrombolytic Effects 0.000 claims 1
Claims (13)
心血管再建術施行後不安定期を経過した後に起こる心血管イベントの発症を予防するための心血管イベント予防用組成物。 Containing ethyl icosapentate as an active ingredient,
A composition for preventing cardiovascular events for preventing the onset of a cardiovascular event that occurs after an unstable period has elapsed after cardiovascular reconstruction.
心血管再建術施行後6ヶ月を経過した後の患者のための心血管イベント発症を予防する心血管イベント予防用組成物。 Containing ethyl icosapentate as an active ingredient,
A composition for preventing cardiovascular events, which prevents the onset of cardiovascular events for a patient who has passed 6 months after cardiovascular reconstruction.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007287366A JP5134916B2 (en) | 2005-07-08 | 2007-11-05 | Composition for preventing cardiovascular events |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005200503 | 2005-07-08 | ||
| JP2005200503 | 2005-07-08 | ||
| JP2007287366A JP5134916B2 (en) | 2005-07-08 | 2007-11-05 | Composition for preventing cardiovascular events |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006188456A Division JP4751257B2 (en) | 2005-07-08 | 2006-07-07 | Composition for preventing cardiovascular events |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012157914A Division JP5809115B2 (en) | 2005-07-08 | 2012-07-13 | Preparation for cardiovascular event prevention |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008050367A JP2008050367A (en) | 2008-03-06 |
| JP2008050367A5 true JP2008050367A5 (en) | 2009-08-13 |
| JP5134916B2 JP5134916B2 (en) | 2013-01-30 |
Family
ID=39234724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007287366A Active JP5134916B2 (en) | 2005-07-08 | 2007-11-05 | Composition for preventing cardiovascular events |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5134916B2 (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110236476A1 (en) | 2008-09-02 | 2011-09-29 | Amarin Corporation Plc. | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
| NZ624963A (en) | 2009-04-29 | 2016-07-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| NZ627238A (en) | 2009-04-29 | 2016-02-26 | Amarin Pharmaceuticals Ie Ltd | Stable pharmaceutical composition comprising ethyl eicosapentaenoate |
| MY172372A (en) | 2009-06-15 | 2019-11-21 | Amarin Pharmaceuticals Ie Ltd | Compositions and methods for lowering triglycerides |
| NZ744990A (en) | 2010-11-29 | 2019-10-25 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| EP2866801A4 (en) | 2012-06-29 | 2016-02-10 | Amarin Pharmaceuticals Ie Ltd | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
| WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
| KR102296068B1 (en) | 2018-09-24 | 2021-09-02 | 애머린 파마슈티칼스 아일랜드 리미티드 | Methods of Reducing the Risk of a Cardiovascular Event in a Subject |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5861399A (en) * | 1996-07-17 | 1999-01-19 | Heart Care Partners | Methods and compositions for the rapid and enduring relief of inadequate myocardial function |
| IT1308613B1 (en) * | 1999-02-17 | 2002-01-09 | Pharmacia & Upjohn Spa | ESSENTIAL FATTY ACIDS IN THE PREVENTION OF CARDIOVASCULAR EVENTS. |
| ITMI20012384A1 (en) * | 2001-11-12 | 2003-05-12 | Quatex Nv | USE OF POLYUNSATURATED FATTY ACIDS FOR THE PRIMARY PREVENTION OF MAJOR CARDIOVASCULAR EVENTS |
| JP2006519244A (en) * | 2003-03-05 | 2006-08-24 | ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | Use of omega-3-fatty acids in the treatment of diabetic patients |
| JP4751257B2 (en) * | 2005-07-08 | 2011-08-17 | 持田製薬株式会社 | Composition for preventing cardiovascular events |
-
2007
- 2007-11-05 JP JP2007287366A patent/JP5134916B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008050367A5 (en) | ||
| JP5809115B2 (en) | Preparation for cardiovascular event prevention | |
| JP5134916B2 (en) | Composition for preventing cardiovascular events | |
| JPWO2009142242A1 (en) | Composition for preventing cardiovascular events in high-risk patients | |
| JP2008509132A5 (en) | ||
| HUP0200111A2 (en) | Use of essential fatty acids for preparation of pharmaceutical composition available in the prevention of cardiovascular events | |
| Malik et al. | Niacin, lipids, and heart disease | |
| McCarty | Policosanol safely down-regulates HMG-CoA reductase–potential as a component of the Esselstyn regimen | |
| Prasad | Antihypertensive activity of secoisolariciresinol diglucoside (SDG) isolated from flaxseed: role of guanylate cyclase | |
| CN109152760B (en) | Methods of treating cholestatic and fibrotic diseases | |
| Kandula et al. | Discovery and preclinical development of a novel prodrug conjugate of mesalamine with eicosapentaenoic acid and caprylic acid for the treatment of inflammatory bowel diseases | |
| ES2230733T3 (en) | STATIN-CARBOXIALQUILETER COMBINATIONS. | |
| US20120282359A1 (en) | Compositions, Kits, and Methods for the Treatment of Conditions Associated with Elevated Cholesterol Levels | |
| Mthembu et al. | Impact of dyslipidemia in the development of cardiovascular complications: delineating the potential therapeutic role of coenzyme Q10 | |
| JP2007238594A (en) | Composition for preventing stroke recurrence | |
| JP5226980B2 (en) | Pharmaceutical composition containing an HMG-CoA reductase inhibitor, tocopherols and CoQ10 | |
| US20190111064A1 (en) | Statin + vitamin d combination drug and method of use | |
| WO2012051107A2 (en) | Niacin formulations and methods with reduced flushing side-effect | |
| JP2007039452A (en) | Composition for preventing occurrence of cardiovascular event | |
| US20050182036A1 (en) | Medicinal composition containing an HMG-CoA reductase inhibitor | |
| JP2006117645A (en) | MEDICINAL COMPOSITION CONTAINING HMG-CoA REDUCTASE INHIBITOR AND GLUTATHIONE | |
| Pande | Approach to lipid therapy in the patient with atherosclerotic vascular disease | |
| JP2006176498A5 (en) | ||
| JP2006176498A (en) | Phermaceutical composition having action of lowering blood free fatty acid | |
| JP2014509305A5 (en) |